Immediate Reconstruction Safe After Previous Irradiation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

SAN ANTONIO--Women who have locoregional cancer recurrence after breast-conserving surgery and radiation therapy can safely undergo immediate breast construction and use of a TRAM flap after mastectomy for the recurrent disease. However, the breast reconstruction procedure should include use of a free flap, which has a lower risk of necrosis and flap loss than pedicle flaps, Bonnie Baldwin, MD, said at the San Antonio Breast Cancer Symposium.

SAN ANTONIO--Women who have locoregional cancer recurrence after breast-conserving surgery and radiation therapy can safely undergo immediate breast construction and use of a TRAM flap after mastectomy for the recurrent disease. However, the breast reconstruction procedure should include use of a free flap, which has a lower risk of necrosis and flap loss than pedicle flaps, Bonnie Baldwin, MD, said at the San Antonio Breast Cancer Symposium.

The difference in outcome between free and pedicle flaps probably relates to inadequate vascularization in mastectomy-site beds in previously irradiated breasts, said Dr. Baldwin, a plastic surgeon at M.D. Anderson Cancer Center.

Dr. Baldwin and her colleagues compared outcomes of immediate reconstruction in two groups of women undergoing mastectomy: Those with locoregional recurrence after previous breast-conserving surgery and irradiation and those with previously untreated breast cancer. The breast conservation cohort included 48 breasts, 27 reconstructed with free TRAM flaps and 21 with pedicle flaps. Reconstruction outcomes were compared with those of 739 previously untreated breasts, 554 reconstructed with free flaps and 185 with pedicle flaps.

The overall complication rate did not differ significantly, 31% in the breast conservation group vs 25% in the previously untreated patients, Dr. Baldwin reported. No significant differences occurred with respect to flap necrosis, infection, fat necrosis, hematoma, or seroma.

The incidence of total flap loss also did not differ between the two groups: 0% in the breast conservation patients and 0.7% in the previously untreated patients. However, partial flap loss occurred significantly more often in the breast conservation group, 12.5% vs 1.6%.

Evaluation of partial flap loss in the breast conservation group showed that all six flap losses occurred in women who had reconstruction with pedicle flaps.

The findings show that immediate breast reconstruction with a TRAM flap can be performed safely in women who have a history of breast conservation and irradiation, Dr. Baldwin said. However, the higher incidence of partial flap loss associated with pedicle flaps supports the use of free TRAM flaps in these patients.

"We prefer to do breast reconstruction with TRAM flaps and skin-sparing mastectomy," Dr. Baldwin said. "We wanted to see if it would be possible to perform reconstruction with TRAM flaps in women who had prior breast-conserving surgery and irradiation. We were successful in that we had no total flap losses, but we did have more problems with partial flap necrosis in pedicle flaps."

The difference, she said, probably relates to the fact that "we were dealing with an irradiated bed. A free flap probably has a better blood supply, compared to a pedicle flap in previously irradiated breasts."

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content